Germany – Pharmaceutical products – Offene Rahmenvereinbarung über Arzneimittelrabatte gemäß § 130a Absatz 8 SGB V mit jederzeitiger Beitrittsmöglichkeit, sogenanntes Zulassungsmodell 2025-02“ der Deutschen Rentenversicherung Knappschaft-Bahn-See

Health · Germany government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

December 05, 2026
Response Due
Active
Status

Opportunity Overview

Germany – Pharmaceutical products – Open framework agreement on drug discounts pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V), with the possibility of joining at any time, so-called "Approval Model 2025-02" of the German Pension Insurance Knappschaft-Bahn-See

This Germany Pharmaceuticals opportunity is one most of your competitors will never see.

How to bid: GlobalGov tracks this tender; it does not accept bids. Submit your response through the issuing agency’s official notice.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start a free GlobalGov account

Solicitation Details

Issuing agencyHealth
CountryGermany
CategoryPharmaceuticals
PublishedDecember 13, 2024
Procurement stageActive solicitation
Response dueDecember 05, 2026
StatusOpen — accepting responses
Original languageGerman — members read it in their own language
Official sourceView original notice
Last verifiedOctober 11, 2026

Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.

Related Opportunities in Germany

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Golimumab (ATC: L04AB06)
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Sulpirid, ATC N05AL01
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Mepolizumab (ATC-Code: R03DX09).
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum WS Ranibizumab (ATC-Code nach WHO: S01LA04) als Injektionslösung in einer Fertigspritze
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Therapie-Allergene, ATC V01AA05
Germany – Pharmaceutical products – Open house drug discount contracts Fingolimod in the strength 0.25 mg, ATC L04AE01
Germany – Pharmaceutical products – Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V) for medicinal products containing the active ingredient Tafluprost (ATC code: S01EE05).
Germany – Pharmaceutical products – Open house drug discount contracts Multienzyme (lipase, protease etc.), ATC A09AA02

See every Germany Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free Germany Pharmaceuticals intelligence report in your inbox

A personalized report on Germany Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.